FDA Approves Modeyso as First Treatment for H3 K27M-Mutant Diffuse Midline Glioma
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the US.
Diffuse Midline Glioma
Latest Post
Efficacy and Safety of Dordaviprone (ONC201) in Prospective Clinical Trials of Adult and Pediatric Recurrent H3 K27M-Mutant Diffuse Glioma Patients
Dordaviprone shows 16.7% response rate in adults with recurrent H3 K27M gliomas, with durable responses...